# Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)

> **NCT04635839** · PHASE4 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 46 (actual)

## Conditions studied

- Pregnancy Related
- Antepartum DVT

## Interventions

- **DRUG:** Standard Dose of Unfractionated Heparin
- **DRUG:** Gestational Age-Based Dose of Unfractionated Heparin

## Key facts

- **NCT ID:** NCT04635839
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-15
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-05-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04635839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04635839, "Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT04635839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*